PC
EPZM

Pier Capital’s Epizyme, Inc EPZM Stock Holding History

Pier Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-574,299
Closed -$6.85M – 127
2020
Q3 		$6.85M Buy
574,299
+219,005
+62% +$2.93M 1% 63
2020
Q2 		$5.71M Buy
355,294
+143,018
+67% +$2.5M 0.91% 65
2020
Q1 		$3.29M Buy
+212,276
New +$4.56M 0.73% 73

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pier Capital's EPZM Position: Q4 2020 in Review

Pier Capital sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 574,299 shares — an estimated $6.85M sold.

Pier Capital first reported a position in EPZM in Q1 2020 and held it in 3 quarters. The position peaked at $6.85M in Q3 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • Pier Capital reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
  • Pier Capital sold 574,299 Epizyme, Inc shares in Q4 2020, an estimated $6.85M.
  • Pier Capital first reported a position in Epizyme, Inc in Q1 2020 and held it in 3 quarters.
  • Pier Capital's Epizyme, Inc position peaked at $6.85M in Q3 2020.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on Pier Capital's 13F filing for Q4 2020, filed 16 Feb 2021.